• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Adenovirus encoding hepatitis C virus vaccine is safe but effectiveness is unclear

bySze Wah Samuel ChanandHarsh Shah
February 10, 2021
in Infectious Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this phase 1-2 clinical trial, an adenovirus viral vector expressing non-structural hepatitis C proteins was safe in a high-risk population.

2. The vaccine did not have a significant impact on chronic hepatitis C infection prevention.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The hepatitis C virus (HCV) is one of the most prevalent blood-borne infections while conferring significant mortality and morbidity. A vaccine strategy is important in reducing the spread among high-risk populations and may be essential in the goal of eliminating the disease. In this randomized trial, participants were either assigned to a recombinant chimpanzee adenovirus 3 vector or placebo group. At six months, there was no significant difference in the rates of chronic HCV infection between vaccine and placebo groups. T-cell responses were detected in the vaccine group and a minimal amount was seen in the placebo group. The percentages of participants with serious adverse events were similar between both groups. The most common serious adverse event was related to increased alanine transaminase (ALT) levels. The limitation of the study was the inability to reveal some level of efficacy in the prevention of HCV infections even though the strategy was shown to be safe. Overall, this trial demonstrates that this vaccine strategy has no evidence of efficacy and highlights the difficulty in formulating an HCV vaccine given chronic infection involves likely immune-escape mechanisms.

Click here to read the study in the NEJM

Relevant Reading: Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection

RELATED REPORTS

The 2 Minute Medicine Podcast Episode 55

The Scan by 2 Minute Medicine®: Triple Attack Against Endometriosis, Vaccines and Autism, Revisited, The Final Frontier of Human Health, and Eating Well to Live Better:

The 2 Minute Medicine Podcast Episode 54

In-Depth [randomized controlled trial]: In this phase 1-2, double-blinded, placebo-controlled randomized trial of 548 participants, participants at risk of HCV infection were enrolled based on a history of recent intravenous drug use were assigned 1:1 to receive vaccine or placebo in a day 0 and day 56 regiment. The vaccine was a recombinant chimpanzee adenovirus 3 vector followed by a recombinant modified vaccinia Ankara boost encoding non-structural proteins of the HCV. The primary endpoint was the rate of chronic HCV infection at 6 months defined by HCV RNA levels. The rate of chronic HCV infection was similar between both groups (hazard ratio [HR] 1.53, 95% confidence interval (CI) of 0.66 to 3.55). The geometric mean peak HCV RNA level was 152 x 103 international units (IU) per milliliter (mL) in the vaccine group compared to 1804 x 103 IU per mL in the placebo group. Immunogenicity was assessed before viral infection. T-cell responses were detected in 78% of the vaccine group and only in 3% of the placebo group. The rate of serious adverse events was similar between both groups, with most events related to a laboratory detected adverse event. The most frequent laboratory detected adverse event was an elevation in the ALT levels which was detected in 50% of the vaccine group and 39% in the placebo group. Overall, the trial determined the adenovirus vaccine strategy was safe; however the effectiveness to prevent subsequent HCV infection was not able to be determined.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adenovirus vectoreffectivenesshepatitis Cvaccinevaccine safety
Previous Post

Tirbanibulin ointment potentially effective for actinic keratosis treatment

Next Post

Nivolumab plus ipilimumab increases overall survival in patients with malignant pleural mesothelioma

RelatedReports

The 2 Minute Medicine Podcast Episode 15
2MM Podcast

The 2 Minute Medicine Podcast Episode 55

April 5, 2025
The Scan by 2 Minute Medicine: The Role of Virtual Reality in Pain Management, WHO’S controversial diagnosis on gaming addictions, the TikTok ban and psychology of doom scrolling, and the risk of smart devices replacing annual checkups
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Triple Attack Against Endometriosis, Vaccines and Autism, Revisited, The Final Frontier of Human Health, and Eating Well to Live Better:

April 1, 2025
The 2 Minute Medicine Podcast Episode 15
2MM Podcast

The 2 Minute Medicine Podcast Episode 54

March 21, 2025
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Measles Outbreak, Tariffs and Healthcare, Pope’s Pneumonia, and Removing Fluoride from Water:

March 18, 2025
Next Post
Quick Take: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial

Nivolumab plus ipilimumab increases overall survival in patients with malignant pleural mesothelioma

Novel coronavirus identified from patients with pneumonia in Wuhan, China

Reduced risk of SARS-CoV-2 with presence of antibodies

#VisualAbstract: Tocilizumab is superior to rituximab for treatment of rheumatoid arthritis in patients with low or absent B-cell lineage expression

#VisualAbstract: Tocilizumab is superior to rituximab for treatment of rheumatoid arthritis in patients with low or absent B-cell lineage expression

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Oral vancomycin may be effective for pouchitis in inflammatory bowel disease
  • Inebilizumab improves outcome in patients generalized myasthenia gravis
  • Medbridge turns any phone into a motion-capture coach for at-home rehab
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.